# Gilead Sciences is appealing lower court rulings that said about 24,000 patients using an HIV drug it produced can pursue negligence claims.

*biotech · news · 2026-05-06 · MarketScreener*

## Key points

- California's Supreme Court is skeptical about requiring drugmakers to develop safer alternatives by law.
- Gilead halted development of TAF in 2004, citing minimal difference from its existing TDF drug.
- Plaintiffs allege Gilead delayed TAF commercialization to coincide with TDF patent expiration in 2017.
- A ruling against Gilead could establish a 'duty to innovate' in product liability law.

**Companies:** Gilead Sciences
**Countries:** United States

[Read the full story on MarketScreener](https://www.marketscreener.com/news/california-s-highest-court-leans-toward-gilead-in-considering-drugmakers-duty-to-innovate-ce7f58d2dd80f326)

---

Canonical: https://newsio.io/n/76697563-3c0c-48fd-be1d-4b348aa758cc/gilead-sciences-is-appealing-lower-court-rulings-that-said-about-24000-patients
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works